Bryleos
Johnson City
About Bryleos
Bryleos is a clinical-stage therapeutics company. It uses the strength of a systems approach to directly address the burden of expensive chronic illnesses. Bryleos has created an oral formulation of NAD+ that is patent-pending and has the ability to support each cell's optimal function using cutting-edge technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.0M
- Funding stage: Seed
- Last round: Seed (Jun 2023)
- Website: bryleos.com
- Phone: [email protected].
Industries & Categories
Biotechnology, Medical, Neuroscience, Product Research
Social Profiles
Canonical: https://fsome.com/organization/bryleos-4933 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.